How to Reconstitute PT-141 (Bremelanotide): Bacteriostatic Water vs Sterile Water

Why the Choice of Diluent Matters

The diluent you choose determines how long reconstituted PT-141 stays stable and whether bacterial contamination becomes a real risk between doses. Bacteriostatic water contains 0.9% benzyl alcohol, a preservative that inhibits microbial growth and extends usable vial life to approximately 28 days under refrigeration. Sterile water contains no preservative, so once the septum is punctured, microorganisms can proliferate within hours.

The United States Pharmacopeia (USP) chapter <797> governs compounded sterile preparations and sets strict beyond-use dating rules based on sterility risk level and whether a preservative is present. USP <797> Pharmaceutical Compounding, Sterile Preparations classifies multi-dose vials without preservative as Category 1 preparations with a beyond-use date (BUD) of no more than 24 hours at controlled room temperature. Vials containing a bacteriostatic agent may qualify for longer BUDs, provided the preparation is stored at 2 to 8 °C and the total duration does not exceed 28 days.

Benzyl Alcohol as a Preservative

Benzyl alcohol at 0.9% concentration has a well-documented antimicrobial track record in pharmaceutical formulations dating back decades. The FDA monograph for bacteriostatic sodium chloride injection (a structurally comparable product) confirms the 0.9% concentration used in BWFI as the accepted preservative level for multi-dose injectable products (FDA label, bacteriostatic sodium chloride). At this concentration, benzyl alcohol works against a broad spectrum of gram-positive and gram-negative bacteria without meaningfully altering peptide structure in short-term storage.

One important caveat: benzyl alcohol is contraindicated in neonates because of gasping syndrome. For adults receiving PT-141 subcutaneously, the cumulative benzyl alcohol exposure per dose is well below the 5 mg/kg threshold associated with toxicity.

Why Sterile Water Falls Short for Multi-Dose Use

SWFI has no preservative, so any particulate or microbial introduction during needle entry is uncontrolled after the first puncture. The CDC guidelines on safe injection practices state clearly that single-dose vials should be discarded after one use, while multi-dose vials require a preservative and must be dated on first opening (CDC, Safe Injection Practices). Using SWFI across multiple draws from the same compounded PT-141 vial is a meaningful infection risk that cannot be offset by refrigeration alone.

Step-by-Step Reconstitution Protocol

Proper technique keeps the peptide intact and the preparation sterile. Each step below reflects standard aseptic compounding practice consistent with USP <797> and basic pharmaceutical science principles for lyophilized peptides.

What You Need Before You Start

• One 10 mg vial of lyophilized PT-141 (Bremelanotide)
• One 10 mL vial of bacteriostatic water for injection (BWFI)
• Two 1 mL insulin syringes (one for drawing BWFI, one for doses)
• Alcohol swabs (70% isopropyl alcohol)
• A clean, flat surface
• A permanent marker and label for dating the vial

The Mixing Procedure

Step 1. Wash hands with soap and water for at least 20 seconds. This is non-negotiable.

Step 2. Swab both vial tops with a fresh alcohol swab. Allow 30 seconds of contact time and let the surface air-dry completely before needle insertion. Wet alcohol on the stopper can carry contaminants into the vial.

Step 3. Draw 2 mL of BWFI into a 1 mL syringe in two 1 mL pulls, or use a 3 mL syringe if available. A 10 mg vial reconstituted with 2 mL yields a concentration of 5 mg/mL. That is the working concentration for all dosing calculations below.

Step 4. Inject BWFI slowly into the PT-141 vial by aiming the stream at the glass wall, not directly onto the powder cake. Direct stream injection shears peptide chains and may cause aggregation. This technique is consistent with general lyophilized peptide reconstitution guidance from the International Journal of Pharmaceutics (Bhambhvani et al., reconstitution techniques for lyophilized biologics, Int J Pharm).

Step 5. Roll gently between your palms for 20 to 30 seconds. Do not shake. Shaking introduces air bubbles and can denature the peptide through mechanical shear stress.

Step 6. Inspect the solution. It should be clear and colorless to very pale yellow. Discard if you see cloudiness, visible particulate, or unusual color.

Step 7. Label the vial with the date of reconstitution and the BUD (28 days from today if using BWFI). Store immediately at 2 to 8 °C.

Dosing Calculator: Drawing the Right Volume

The FDA-approved Vyleesi auto-injector delivers exactly 1.75 mg of bremelanotide per dose (FDA Prescribing Information, Vyleesi). Compounded PT-141 is used off-label and the dose prescribed by a clinician may differ, but 1.75 mg is the most common starting dose. At a 5 mg/mL working concentration, the table below converts doses to syringe volumes.

| Prescribed Dose | Volume to Draw (5 mg/mL) | Insulin Syringe Units (100-unit/mL) | |---|---|---| | 0.5 mg | 0.10 mL | 10 units | | 1.0 mg | 0.20 mL | 20 units | | 1.25 mg | 0.25 mL | 25 units | | 1.75 mg | 0.35 mL | 35 units | | 2.0 mg | 0.40 mL | 40 units | | 2.5 mg | 0.50 mL | 50 units |

If your prescribing clinician specifies a different reconstitution volume, recalculate using this formula: Volume (mL) = Dose (mg) / Concentration (mg/mL).

What Happens If You Use a Different Reconstitution Volume

Some protocols call for 1 mL of BWFI per 10 mg vial, yielding 10 mg/mL. Others use 4 mL, yielding 2.5 mg/mL. The peptide is stable at any of these concentrations within the standard refrigerated storage window, but the syringe volumes change proportionally. Always confirm the concentration on the vial label before drawing a dose. Dosing errors in peptide therapy are almost always a result of concentration confusion, not a fundamental pharmacology problem.

Syringe Selection for PT-141 Subcutaneous Injection

Why Insulin Syringes Work Best

A 0.5 mL or 1 mL insulin syringe with a 28 to 31 gauge, 5/16-inch (8 mm) needle is the standard choice for subcutaneous PT-141 administration. The gauge is fine enough to minimize pain and bruising at the injection site. The short needle length reaches the subcutaneous fat layer in most adults without risking intramuscular injection. The FDA-approved Vyleesi device itself delivers a subcutaneous injection into the abdomen or thigh (FDA Prescribing Information, Vyleesi, 2019), confirming the subcutaneous route as the clinically validated delivery path for bremelanotide.

Reading an Insulin Syringe for Peptide Dosing

Insulin syringes are calibrated in units, not mL, based on U-100 insulin (100 units = 1 mL). For peptide dosing, treat each "unit" on the barrel as 0.01 mL. So 35 units = 0.35 mL = 1.75 mg at a 5 mg/mL concentration. This unit-to-mL equivalency is fixed regardless of what medication is in the syringe.

Injection Technique

Pinch a fold of skin on the lower abdomen (2 inches from the navel) or outer thigh. Insert the needle at a 45-degree angle for leaner individuals or 90 degrees with adequate subcutaneous tissue. Inject slowly over 5 seconds. Release the skin fold, withdraw the needle, and apply gentle pressure with a dry cotton ball. Do not rub. Rubbing disperses the peptide unevenly through the tissue.

Pharmacology and Clinical Evidence for PT-141

Mechanism of Action

PT-141 (Bremelanotide) is a melanocortin receptor agonist. It acts primarily on MC3R and MC4R receptors in the central nervous system to increase sexual desire through a non-vascular, centrally mediated pathway. This mechanism is distinct from PDE5 inhibitors like sildenafil, which act peripherally on vascular smooth muscle. A 2008 paper by Molinoff et al. In the Annals of the New York Academy of Sciences characterizes bremelanotide's receptor selectivity and central action (Molinoff et al., 2003, Ann NY Acad Sci).

Phase 3 Trial Data

The FDA approval of Vyleesi rested on two Phase 3 randomized controlled trials, RECONNECT Study 1 and Study 2, both published in Obstetrics and Gynecology. Combined enrollment across both studies was 1,267 premenopausal women with hypoactive sexual desire disorder (HSDD). At 24 weeks, women receiving bremelanotide 1.75 mg subcutaneously reported statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain score compared with placebo (P<0.001 in both studies). Simultaneously, distress scores on the Female Sexual Distress Scale-Desire (FSDS-DAO) decreased significantly in the treatment group (Simon et al., Obstet Gynecol, 2019).

Nausea was the most common adverse event, reported in 40.2% of bremelanotide-treated participants vs. 1.2% placebo. Flushing occurred in 20.4% vs. 0.8%. Transient blood pressure increases of approximately 6 mmHg systolic and 3 mmHg diastolic were observed, resolving within 12 hours. These adverse event rates are documented in the FDA prescribing information for Vyleesi (FDA, Vyleesi PI, 2019).

Off-Label Use in Men

PT-141 has been studied in men with erectile dysfunction. A Phase 2 dose-escalation trial by Rosen et al. (2004) found that intranasal bremelanotide produced erectile responses in men with psychogenic erectile dysfunction, with dose-dependent increases in rigidity measured by RigiScan (Rosen et al., 2004, Int J Impot Res). Subcutaneous administration is now preferred over intranasal due to more predictable pharmacokinetics and avoidance of blood pressure spikes associated with higher intranasal doses.

Stability: How Long Does Reconstituted PT-141 Last?

Lyophilized vs. Reconstituted Stability

Lyophilized (freeze-dried) PT-141 powder is stable at room temperature for extended periods, typically 24 months when stored below 25 °C and protected from light. Once reconstituted, the peptide is in aqueous solution and subject to hydrolysis, oxidation, and microbial degradation. The stability clock starts at the moment of first needle puncture.

Peptide stability in aqueous solution varies by amino acid composition, pH, and temperature. Bremelanotide (cyclo[Nle4, D-Phe7]-alpha-MSH analog) contains a disulfide-like cyclic structure that confers greater hydrolytic stability than many linear peptides, but it is not immune to degradation.

Beyond-Use Dating by Diluent Type

| Diluent | Storage Condition | Recommended BUD | |---|---|---| | BWFI (0.9% benzyl alcohol) | 2 to 8 °C (refrigerated) | 28 days | | SWFI (no preservative) | 2 to 8 °C | 24 hours | | SWFI (no preservative) | Room temperature | 4 hours |

These BUDs align with USP <797> Category 1 guidelines for low-risk compounded sterile preparations (FDA, USP <797> Overview). Individual compounding pharmacies may specify shorter BUDs based on their sterility testing results and internal protocols.

Signs of Degradation

Discard the vial if you notice:

• Cloudiness or visible particulate matter
• Color change (pale yellow is acceptable; dark yellow or brown is not)
• Unusual odor on withdrawal
• The vial has exceeded its labeled BUD

Common Reconstitution Errors and How to Avoid Them

The following error-prevention framework is used by the HealthRX clinical team when reviewing patient reconstitution logs. It covers the five most frequent mistakes encountered in compounded peptide administration.

Error 1: Wrong Volume of Diluent

Adding 1 mL instead of 2 mL doubles the concentration to 10 mg/mL. At that concentration, the 1.75 mg dose requires only 0.175 mL (17.5 units). Patients who are not recalculating can inadvertently take 3.5 mg per injection, which nearly doubles the rate of nausea and flushing. Always write the final concentration on the vial label in large text.

Error 2: Shaking Instead of Rolling

Vigorous shaking produces foam and mechanical shear. Both can denature peptide secondary structure. A 30-second gentle roll between palms is sufficient to dissolve the lyophilized cake in most cases. If powder remains after 60 seconds, tilt and roll rather than shaking.

Error 3: Storing Outside the Refrigerator

Leaving reconstituted PT-141 at room temperature overnight does not simply shorten shelf life by one day. It accelerates hydrolytic degradation exponentially, consistent with Arrhenius kinetics for peptide degradation in solution. A single 8-hour room temperature excursion may degrade the peptide enough to reduce clinical effect, though visual inspection will appear unchanged. Refrigerate within 30 minutes of reconstitution.

Error 4: Reusing Syringes

Needle tips deform after a single injection. A used needle creates a larger puncture wound, increases pain, and can introduce skin flora into the vial on re-entry. Use a fresh syringe for each dose draw.

Error 5: Using Tap Water or Normal Saline

Tap water is not sterile, is not pyrogen-free, and contains minerals that may precipitate with the peptide. Normal saline (0.9% NaCl) is sometimes proposed as an alternative to SWFI, but commercial saline vials are typically single-dose and have no preservative. BWFI remains the correct diluent for multi-dose compounded PT-141.

Regulatory and Safety Context

FDA Approval of Vyleesi

The FDA approved bremelanotide (Vyleesi) on June 21, 2019, for the treatment of acquired, generalized HSDD in premenopausal women (FDA Press Announcement, June 2019). The approved product is a single-dose, pre-filled auto-injector containing 1.75 mg bremelanotide in 0.4 mL sterile solution for subcutaneous injection. The FDA prescribing information specifically contraindicates Vyleesi in patients with cardiovascular disease due to the transient blood pressure increase.

Compounded PT-141 vs. Vyleesi

Compounded PT-141 is not FDA-approved and is prepared under state pharmacy board authority and USP <797> standards. Compounding may be appropriate when a patient requires doses that differ from 1.75 mg, when cost is a barrier, or when a clinician determines the approved formulation is not available. The FDA's guidance on compounding makes clear that compounded preparations are not bioequivalent substitutes for approved drug products (FDA, Human Drug Compounding).

Patients using compounded PT-141 should obtain their supply from an FDA-registered 503B outsourcing facility or a state-licensed 503A pharmacy operating under a valid prescription.

Cardiovascular Precautions

The Endocrine Society and the FDA both note the transient pressor effect of bremelanotide. Blood pressure may rise by up to 6 mmHg systolic within 1 hour of injection, with return to baseline by 12 hours. Patients with uncontrolled hypertension, known cardiovascular disease, or a baseline systolic blood pressure above 150 mmHg should not use bremelanotide without explicit physician clearance. The RECONNECT trials excluded participants with a history of cardiovascular disease (Simon et al., Obstet Gynecol, 2019).

Timing, Frequency, and Storage Summary

Timing of Administration

Inject PT-141 subcutaneously approximately 45 minutes before anticipated sexual activity. The FDA-approved Vyleesi label specifies this window based on pharmacokinetic data showing peak plasma concentrations at approximately 1 hour post-injection (FDA Prescribing Information, Vyleesi, 2019). The prescribing information also states patients should not use more than one dose within 24 hours and no more than approximately 8 doses per month based on the trial protocol.

Frequency Limits

In the RECONNECT trials, participants used bremelanotide as-needed, not on a fixed daily schedule. The mean number of uses per month was approximately 2 to 3 across both studies. Daily use was not evaluated in Phase 3 and is not recommended given the cumulative blood pressure effects and high nausea rate.

Cold Chain Logistics

Keep reconstituted vials at 2 to 8 °C at all times. Do not freeze. Freezing reconstituted peptide solutions causes ice crystal formation, which physically disrupts the peptide's tertiary structure and reduces potency. If a vial has been accidentally frozen, discard it.